Abstract:e17523 Background: Germline DNA repair gene (DRG) mutations has emerged as a potential determinant of cancer risk and therapeutic response in PCa. Despite substantial advances in delineating the germline mutation in DRGs among Caucasian population, the prevalence of mutations in DRGs are largely unknown among a large series of unselected prostate cancer patients in Chinese population. Methods: We enrolled 1003 prostate cancer patients from three different hospitals in China, unselected for family history of cancer or age at diagnosis. All patients received germline genetic testing using a clinician-selected multi-gene panel. The 18 DNA repair genes and HOXB13, which has established or emerging potential clinical actionability in PCa, were analyzed in our study. Results: A total of 94 (9.7%) deleterious germline mutations were identified among the 1003 unselected prostate cancer patients. Of these, 5.6% patients carried a BRCA1 or BRCA2 mutations (5.2% in BRCA2 and 0.4% in BRCA1), 3.6% patients carried other DRG mutations (including 10 genes) and 0.5% patients carried HOXB13 mutations. Besides, variants with uncertain significance (VUS) were found in approximately 45% patients. We also divided 633 metastatic PCa patients into 542 de novo metastastic PCa and 91 recurrent metastastic PCa and found mutation frequencies did not differ between these two groups (9.0% vs 11.6%, p = 0.6). Patients with younger age of onset or family history of cancers were more likely to harbour germline mutations in DRGs. However, the rate of germline mutations were still at a high level for patients more than 70 years old (6.7%) and patients without family history of cancers (7.5%). There is no statistically significant difference in the mutation frequencies between patients with metastasis and without metastasis (7.5% vs 9.2%, p = 0.4), which may be because 85% patients without metastasis in our cohort were in high to very high risk group or have lymph node metastasis. Conclusions: To our knowledge, our study reported the largested series of Chinese PCa patients who received germline genetic testing. Our study provided a rationality for germline genetic testing criteria from high risk to metastastic PCa regardless of family history considering the high proportion. In addition, we recommended a multigene panel covering 13 genes ( ATM, BRCA1, BRCA2, CHEK2, FANCA, HOXB13, MSH2, MSH6, NBN, PALB2, RAD51C, RAD51D, TP53) in China. Nevertheless, the high prevalence of VUS (45%) in Chinese PCa patients warrant further efforts.

Clinical relevance of protein-truncating variants of germline DNA repair genes in prostate cancer

Germline Mutations in DNA Repair Genes in a Large Series of Unselected Chinese Prostate Cancer Patients.

Truncating Variants in P53aip1 Disrupting DNA Damage-Induced Apoptosis Are Associated with Prostate Cancer Risk

Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer

Mechanistic insights into genetic susceptibility to prostate cancer

Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.

Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer

Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases

Prostate cancer genotyping for risk stratification and precision treatment

Inherited Mutations in Chinese Men With Prostate Cancer

TEX15: A DNA repair gene associated with prostate cancer risk in Han Chinese.

Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture

Prevalence of comprehensiveDNAdamage repair gene germline mutations in Chinese prostate cancer patients

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage

Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients

Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer

Genetic variants in RNA-induced silencing complex genes and prostate cancer

Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations.

Susceptibility of XPD and Hogg1 Genetic Variants to Prostate Cancer

Genome-wide Association Study (GWAS) of Germline Copy Number Variations (CNVs) Reveal Genetic Risks of Prostate Cancer in Chinese population.

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.